Menopause care provider Minter Hormone Health wins Femtech and Women’s Health competition
The Femtech & Women’s Health edition of ‘Discovery Spark’ supports early stage businesses working to close the gender health gap
News
Anglia Innovation Partnership, the campus management organisation at Norwich Research Park, hosted its latest Enterprise Tuesday event on Tuesday 11 June at the John Innes Conference Centre, showcasing novel technology platforms and debating the value of ‘science push and industry pull’ activity in the cluster.
CCDC Scientist Awarded Prestigious BACG Young Scientists Award
Dr Pietro Sacchi Wins the Award for Ground-Breaking Work Providing Practical Solutions to Long-Standing Challenges in Drug Development and Manufacturing
Cambridge, UK – 12 July 2024 – We are pleased to announce that Dr Pietro Sacchi, Research and Application Scientist at the CCDC, has been awarded the British Association for Crystal Growth (BACG) Young Scientists Award for his exceptional research on the HIV drug ritonavir.
The pharmaceutical landscape is evolving rapidly, and staying ahead requires a deep understanding of the current trends and challenges. This comprehensive report provides a critical analysis of the drug development industry, focusing on the health of pipelines, the strategic focus of biotechs and pharmacos, and the capacity of regulators like the FDA to manage the influx of novel therapies.
AMSBIO offers a wide range of products to support skeletal muscle cell culture enabling you to streamline your modelling process in vitro.
With the new Labour government pledging to 'build an NHS fit for the future', an injection of money, whilst welcome, will not be enough - it must be rolled out in a measured and integrated way that works more closely with the private sector in order to make a real difference, says RSM UK.
Presentation in Boston at 9th Microbiome Movement Drug Development Summit, 10-12 July 2024
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth.